Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
Vise andre og tillknytning
2010 (engelsk)Inngår i: American Journal of Hypertension, ISSN 0895-7061, E-ISSN 1941-7225, Vol. 23, nr 7, s. 786-793Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background 

Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes. However, whether concomitant hydrochlorothiazide (HCTZ) therapy in >70% of LIFE patients was associated with greater regression of LVH independent of BP changes and whether this effect differed between treatment arms has not been examined.

Methods 

Changes in Cornell product and Sokolow–Lyon voltage LVH were assessed in 9,193 hypertensive patients randomly assigned to treatment with losartan or atenolol, with additional HCTZ therapy added as necessary to achieve target BP goal per study protocol.

Results 

After controlling for baseline and change in systolic and diastolic pressure, age, sex, race, prior antihypertensive treatment, baseline and year-4 body mass index and baseline LVH by either Cornell product or Sokolow–Lyon voltage, at year-4 follow-up HCTZ therapy was associated with greater regression of Cornell product LVH (−244 ± 788 vs. −172 ± 771 mm·msec, P < 0.05) and Sokolow–Lyon voltage (−4.2 ± 6.7 vs. −3.0 ± 7.0 mm, P < 0.001) and this effect was significantly greater in patients on losartan (−341 ± 743 vs. −189 ± 775 mm·msec and −5.2 ± 6.6 vs. −3.3 ± 6.6 mm) than in patients on atenolol (−142 ± 822 vs. −158 ± 765 mm·msec and −3.1 ± 6.6 vs. −2.7 ± 7.4 mm; both P < 0.001 for interaction of HCTZ with losartan vs. atenolol therapy).

Conclusions 

HCTZ use was associated with greater regression of ECG LVH and this effect was greater in patients on losartan- than atenolol-based therapy, independent of baseline severity of ECG LVH and hypertension and changes in BP.

sted, utgiver, år, opplag, sider
2010. Vol. 23, nr 7, s. 786-793
Emneord [en]
blood pressure; drugs; electrocardiography; hypertension
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-41555DOI: 10.1038/ajh.2010.65ISI: 000279119700017Scopus ID: 2-s2.0-77953810908OAI: oai:DiVA.org:umu-41555DiVA, id: diva2:406834
Tilgjengelig fra: 2011-03-28 Laget: 2011-03-28 Sist oppdatert: 2023-03-24bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Person

Lindholm, Lars H

Søk i DiVA

Av forfatter/redaktør
Lindholm, Lars H
Av organisasjonen
I samme tidsskrift
American Journal of Hypertension

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 264 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf